{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:10:20Z","timestamp":1778181020846,"version":"3.51.4"},"reference-count":59,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Biliary tract cancers (BTCs) are rare and aggressive malignancies with an increasing incidence and poor prognosis. The standard systemic treatment for BTCs has evolved to include immune checkpoint inhibitors associated with gemcitabine\u2013cisplatin as first-line therapies. However, survival rates remain low, highlighting the critical need for personalized treatment strategies based on molecular profiling. Currently, significant advancements have been made in the molecular characterization of BTCs, where genetic alterations, such as IDH1 mutations and FGFR2 fusions, provide targets for therapy. Molecular profiling is crucial early in the management process to identify potential candidates for clinical trials and guide treatment strategy. The integration of these molecular insights into clinical practice has allowed for the development of targeted therapies, although many of them are still in the phase 2 trial stage without definitive survival benefits demonstrated in phase 3 trials. This integration of comprehensive molecular profile insights with traditional treatment approaches offers a new horizon in the personalized medicine landscape for BTCs, with the aim of significantly improving patient outcomes through precision oncology.<\/jats:p>","DOI":"10.3390\/curroncol31070266","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T12:27:33Z","timestamp":1718972853000},"page":"3615-3629","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrating Molecular Insights into Biliary Tract Cancer Management: A Review of Personalized Therapeutic Strategies"],"prefix":"10.3390","volume":"31","author":[{"given":"Mar","family":"Ros-Bux\u00f3","sequence":"first","affiliation":[{"name":"School of Medicine, Universitat de Barcelona, 08007 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-7676","authenticated-orcid":false,"given":"Ezequiel","family":"Mauro","sequence":"additional","affiliation":[{"name":"School of Medicine, Universitat de Barcelona, 08007 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), 28029 Madrid, Spain"},{"name":"Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Institut Cl\u00ednic de Malalties Digestives i Metab\u00f2liques (ICMDM), Hospital Clinic Barcelona, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7479-5120","authenticated-orcid":false,"given":"Tamara","family":"Sauri","sequence":"additional","affiliation":[{"name":"School of Medicine, Universitat de Barcelona, 08007 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Barcelona Clinic Liver Cancer (BCLC) Group, Medical Oncology Department, Institut del C\u00e0ncer i Malalties de la Sang (ICAMS), Hospital Clinic Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Iserte","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), 28029 Madrid, Spain"},{"name":"Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Institut Cl\u00ednic de Malalties Digestives i Metab\u00f2liques (ICMDM), Hospital Clinic Barcelona, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Fuster-Anglada","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), 28029 Madrid, Spain"},{"name":"Barcelona Clinic Liver Cancer (BCLC) Group, Pathology Department, CDB, Hospital Clinic Barcelona, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-7085","authenticated-orcid":false,"given":"Alba","family":"D\u00edaz","sequence":"additional","affiliation":[{"name":"School of Medicine, Universitat de Barcelona, 08007 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), 28029 Madrid, Spain"},{"name":"Barcelona Clinic Liver Cancer (BCLC) Group, Pathology Department, CDB, Hospital Clinic Barcelona, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4025-0288","authenticated-orcid":false,"given":"Laura","family":"Sererols-Vi\u00f1as","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9731-3913","authenticated-orcid":false,"given":"Silvia","family":"Affo","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-4950","authenticated-orcid":false,"given":"Alejandro","family":"Forner","sequence":"additional","affiliation":[{"name":"School of Medicine, Universitat de Barcelona, 08007 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), 28029 Madrid, Spain"},{"name":"Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Institut Cl\u00ednic de Malalties Digestives i Metab\u00f2liques (ICMDM), Hospital Clinic Barcelona, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.aohep.2023.101185","article-title":"From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America","volume":"29","author":"Mauro","year":"2024","journal-title":"Ann. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","article-title":"Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma","volume":"57","author":"Palmer","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mauro, E., Ferrer-F\u00e0brega, J., Sauri, T., Soler, A., Cobo, A., Burrel, M., Iserte, G., and Forner, A. (2023). New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy. Cancers, 15, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/36831586\/.","DOI":"10.3390\/cancers15041244"},{"key":"ref_8","unstructured":"European Association for the Study of the Liver (2023). EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J. Hepatol., 69, 182\u2013236. Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/37084797\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Lamarca","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_11","first-page":"S19","article-title":"Updated overall survival from the phase 3 TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in patients with advanced biliary tract cancer. (Abstract 56P)","volume":"33","author":"Oh","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114000","DOI":"10.1016\/j.ejca.2024.114000","article-title":"Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","volume":"202","author":"Roth","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gutjnl-2023-330029","article-title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","volume":"73","author":"Rushbrook","year":"2023","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma\u2014Novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/j.annonc.2023.04.399","article-title":"P-343 The impact of genomic alterations on response rate and survival outcomes in advanced BTC patients who receive cisplatin\/gemcitabine plus durvalumab in clinical practice","volume":"34","author":"Rimini","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.11.006","article-title":"Cholangiocarcinoma: What are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine?","volume":"179","author":"Roth","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41591-021-01448-w","article-title":"Limited evolution of the actionable metastatic cancer genome under therapeutic pressure","volume":"27","author":"Hoes","year":"2021","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","article-title":"ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma","volume":"28","author":"Verdaguer","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for Precision Medicine in Biliary Tract Cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): Amulticentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1080\/17474124.2021.1991313","article-title":"Cholangiocarcinoma: New perspectives for new horizons","volume":"15","author":"Rimini","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/bjc.2017.330","article-title":"A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours","volume":"117","author":"Papadopoulos","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study","volume":"35","author":"Nogova","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF\/FGFR Aberrations: A Phase I Dose-Expansion Study","volume":"12","author":"Bahleda","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/10781552231171079","article-title":"Updates in the use of targeted therapies for the treatment of cholangiocarcinoma","volume":"29","author":"Lodl","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/j.annonc.2023.09.1388","article-title":"95MO Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory\/relapsed cholangiocarcinoma","volume":"34","author":"Javle","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: A multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): A multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in Patients with Tumors with BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.23.01193","article-title":"Trastuzumab Plus Gemcitabine-Cisplatin for Treat-ment-Na\u00efve Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB)","volume":"42","author":"Ostwal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Valery, M., Vasseur, D., Fachinetti, F., Boil\u00e8ve, A., Smolenschi, C., Tarabay, A., Antoun, L., Perret, A., Fuerea, A., and Pudlarz, T. (2023). Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments. Cancers, 15.","DOI":"10.3390\/cancers15184446"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion\u2013positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation","volume":"41","author":"Yaeger","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic Determinants of Outcome in Intrahepatic Cholangi-ocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: A prospective case-series","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ajt.16906","article-title":"Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"McMillan","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2100510","DOI":"10.1200\/PO.21.00510","article-title":"Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precis. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/266\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:02:42Z","timestamp":1760108562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["curroncol31070266"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31070266","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]}}}